47 results about "IgA antibody" patented technology

Provided herein are antibodies and functional fragments thereof for the treatment or prophylaxis of viral diseases, such as poxvirus diseases, such as Chenpox and monkey pox. Any antibody or functional fragment thereof described herein may be an engineered antibody or an engineered antibody fragment. In addition, provided herein are compositions and pharmaceutical compositions containing one or more antibodies or functional fragments thereof. Also provided herein are kits containing one or more antibodies or functional fragments thereof, as well as methods, dosing regimens, dosage amounts, and pathways for administering one or more antibodies and one or more functional fragments thereof. Finally, methods of making the antibodies and functional fragments thereof are provided.

The invention concerns homogenous antibody-conjugates with high payload loading (high DAR) obtained by site-specific conjugation to a single antibody N-glycan. The conjugates according to the invention are homogeneous, i.e. have a DAR at or close to the theoretical DAR with a narrow distribution, and do not require any genetic modification of the antibody. The invention further concerns a modular, non-genetic preparation method for such conjugates, involving three simple steps and starting from any antibody. These steps are (a) enzymatic remodeling of the glycan to give an antibody functionalized with two or four click probes per antibody, (b) strain-promoted cycloaddition with a multivalent, bifunctional reagent comprising one cyclic alkyne and at least two click probes that are not reactive towards the cyclic alkyne, and (c) inverse electron-demand Diels-Alder cycloaddition of the click probes with branched linker-drug constructs comprising one cyclic alkyne or strained alkene, connected to one or more payloads preferably connected through a cleavable linker. The resulting conjugates, with DAR6 or higher, are rapidly generated with high homogeneity and with surprising stability. In addition, HIC profiles of the resulting ADCs indicate small relative retention time and therefore show high potential in the targeting of tumour cells and / or the treatment of cancer.

To provide a novel preventative / therapeutic agent which leads to the complete curing and treatment of IgA nephropathy.SOLUTION: This IgA nephropathy preventative / therapeutic agent targets anti-β2 spectrin IgA antibody-induced tonsillar indigenous bacteria.SELECTED DRAWING: None

Provided herein are engineered IgA antibodies that comprises: (a) an EGFR binding domain and (b) an IgA heavy chain constant region. Also, provided herein are methods of treating cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of the engineered antibody.

To provide an improved antibody-drug conjugate and a pharmaceutical composition containing the antibody-drug conjugate.SOLUTION: The invention is based on the concept that it is possible to generate antibodies that exhibit improved potency (e.g., one or more of increased (e.g., detectable increase) toxin release in target mammalian cells, increased (e.g., detectable increase) killing of target mammalian cells, and increased (e.g., detectable increase) endolysosomal delivery). In some embodiments of any of the antibodies described herein, the heavy chain CH1 - CH2 - CH3 sequence consisting of the specific sequence comprises a substitution of lysine to cysteine at amino acid position 105 and a deletion of threonine at amino acid positions 106 and 108.SELECTED DRAWING: None

Provided herein are engineered antibodies comprising modified IgA heavy chain constant regions, pharmaceutical compositions, and methods of use. The engineered antibodies described herein comprise one or more amino acid substitutions or deletions in the constant region of an IgA domain. Also provided herein are methods of treating disorders, including cancer, by administering the engineered IgA antibodies described herein.

The present invention relates to a method of in vitroprediction of the in vivoefficacy in a patient of treatment with a drug product based on an overall assessment of the properties patients own immune cells when exposed to the drug product with and / 0 or without stimulation; the drug product when exposed to said patients own immune cells; and any preexisting antibodies against said drug product in said patient.

The invention belongs to the technical field of detection, and particularly relates to an anti-swine IgA monoclonal antibody and application thereof in PEDV IgA antibody detection. The invention provides an anti-swine IgA monoclonal antibody and a sequence thereof, the monoclonal antibody is effective to swine IgA, but is ineffective to swine immune globulins IgG, IgM, IgD and IgE, and has good reactivity and specificity. According to the invention, an anti-swine IgA monoclonal antibody is labeled on lanthanide EU3 + fluorescent microspheres, and a time-resolved immunofluorescence test strip detection method is established and is used for qualitative detection of an IgA antibody. The detection method is wide in detection range, high in sensitivity and rapid in detection; good repeatability, accuracy and stability are achieved; in addition, the monoclonal antibody has no cross reaction with porcine immune globulins IgG, IgM, IgD and IgE, is high in specificity, has a clinical detection coincidence rate higher than 97.3%, and has strong clinical application potential.

Non-human animals (and / or non-human cells) and methods of using the same are provided, which non-human animals (and / or non-human cells) have a genome comprising human antibody-encoding sequences (i.e., immunoglobulin genes). Non-human animals described herein express antibodies that are of IgA, IgD, or IgM isotypes. Non-human animals provided herein are, in some embodiments, characterized by expression of IgA antibodies that contain human heavy chain and light chain variable domains and rodent constant domains. Methods for producing antibodies from non-human animals are also provided, which antibodies contain human variable regions and rodent constant regions.

Non-human animals (and / or non-human cells) and methods of using the same are provided, which non-human animals (and / or non-human cells) have a genome comprising human antibody-encoding sequences (i.e., immunoglobulin genes). Non-human animals described herein express antibodies that are of IgA, IgD, or IgM isotypes. Non-human animals provided herein are, in some embodiments, characterized by expression of IgA antibodies that contain human heavy chain and light chain variable domains and rodent constant domains. Methods for producing antibodies from non-human animals are also provided, which antibodies contain human variable regions and rodent constant regions.

The present application relates to the technical field of antibody detection, in particular to a TGEV IgA antibody fluorescent microsphere immunochromatography test strip and preparation and application thereof.The TGEV IgA antibody fluorescent microsphere immunochromatography test strip comprises a base plate, and a sample pad, a nitrocellulose membrane and a water absorption pad which are sequentially and lapped and pasted on the base plate; the sample pad is a glass fiber membrane, and the glass fiber membrane is coated with a fluorescent microsphere labeled TGEV-S1 recombinant protein conjugate and a fluorescent microsphere labeled rabbit IgG antibody conjugate; the nitrocellulose membrane is provided with a detection line and a quality control line, wherein the detection line is coated with a goat anti-pig IgA antibody, and the quality control line is coated with a goat anti-rabbit IgG antibody.The test strip can accurately capture low-titer TGEV IgA antibodies, is suitable for high-throughput rapid on-site detection, and has the characteristics of low reagent cost and detection difficulty, high sensitivity and high specificity.

The invention belongs to the field of biology, and discloses a PDCoV recombinant RBD protein and an IgA Elisa kit thereof, and the amino acid sequence of the recombinant RBD protein is as shown in SEQ ID NO. 1. The recombinant RBD protein is used for an indirect ELISA kit, can cover IgA response in the early stage of infection, can accurately recognize a PDCoV specific IgA antibody in a breast milk sample, and cannot cause false positive due to infection of other common pathogens in a pig herd; the indirect ELISA kit is good in stability (the intra-batch variation coefficient is 1.848%-6.062%, and the inter-batch variation coefficient is 4.504%-7.790%), the coincidence rate of the indirect ELISA kit and an immunofluorescence experiment reaches 93.26%, the repeatability and the coincidence rate are high, and the indirect ELISA kit has the advantages of simplicity and convenience in operation, short time consumption and large detection flux of an ELISA method, and is suitable for large-scale screening of clinical pig milk samples.

Provided herein are engineered antibodies that comprise a modified IgA heavy chain constant region, pharmaceutical compositions, and methods of use. The engineered antibodies described herein comprise one or more amino acid substitution or deletion in a constant region of an IgA domain. Further provided herein are methods of treating disorders, including cancer, by administering an engineered IgA antibody described herein.

The application discloses an IgA antibody targeting neurotrophic factors BDNF and NGF and application thereof. The IgA antibody targeting BDNF and NGF is obtained by expression and purification of expression plasmids thereof in HEK-293T cells, and the two IgA antibodies can specifically recognize and combine with BDNF and NGF respectively and have high affinity. The results of examples show that the IgA antibody targeting NGF and BDNF provided by the application can inhibit the growth, proliferation and survival of glioma cells, induce apoptosis of the glioma cells, and reduce the migration and invasion abilities of the cells, and the IgA antibody can also penetrate the blood-brain barrier and reach the glioma tissue to exert a significantly stronger anti-tumor effect compared with IgG antibodies.

The invention belongs to the technical field of immunochromatography detection, and particularly relates to a time-resolved fluorescence immunochromatography test strip for acute stress syndrome detection as well as a preparation method and application of the time-resolved fluorescence immunochromatography test strip. An IgA antibody is introduced into a detection system to serve as a quality control or recognition element, and the detection specificity and stability are further enhanced. By utilizing the IgA antibody, not only can the compatibility of the reagent and the sample be improved, but also the signal strength can be enhanced through the multivalent binding characteristic of the IgA antibody, so that the detection sensitivity is remarkably improved. Therefore, the subtle fluctuation of cortisol and other hormones in the acute stress state can be more clearly captured, the physiological change of the stress reaction is more obviously reflected, and a more accurate, convenient and reliable tool is provided for early screening, auxiliary diagnosis and curative effect evaluation of mental and psychological diseases.

The application discloses an indirect ELISA kit for rapidly detecting porcine epidemic diarrhea virus IgA antibody and application thereof and belongs to the technical field of immunology. The application provides a recombinant PEDV-RBD protein, and an amino acid sequence of the recombinant PEDV-RBD protein is shown as SEQ ID NO. 3. The application constructs an indirect ELISA kit for detecting porcine epidemic diarrhea virus IgA antibody based on the recombinant PEDV-RBD protein, can accurately capture PEDV IgA antibody in sow milk or serum to realize detection, has the advantages of high sensitivity and strong specificity, and provides a technical means for prevention and control of porcine epidemic diarrhea.

The present disclosure relates to: a method, a composition, and a method for producing the same for treating IBD using gastrointestinal contents or excretions modified with an IgA antibody; a method for obtaining an IgA antibody that restores the bacterial flora in the gastrointestinal tract of an IBD patient; a method, a composition, and a method for producing the same for modifying gastrointestinal contents or excretions of an IBD patient using an IgA antibody; and a method, a composition, and a method for producing the same for testing with the diagnostic pharmaceutical drug containing an IgA antibody in a patient treated with the IBD therapeutic agent containing gastrointestinal contents or excretions.

The invention discloses an IgG and IgA antibody detection kit based on porcine rotavirus VP8 protein as well as a preparation method and application of the IgG and IgA antibody detection kit. The kit comprises an elisa plate, positive control serum, negative control serum, an elisa secondary antibody, a sample diluent, a 20-time concentrated washing solution, a substrate solution A, a substrate solution B and a stop solution, wherein the elisa plate is coated with VP8 truncated protein of a porcine rotavirus epidemic strain expressed by mammalian cells. According to the kit, the IgG antibody and the IgA antibody of the porcine rotavirus can be detected at the same time under the condition that only one reagent (enzyme-labeled antibody) is added, and evaluation on the titer of the whole antibody is facilitated. The kit disclosed by the invention is high in sensitivity, high in specificity, good in stability, convenient to operate and relatively high in universality, and has a good market prospect.

The application belongs to the field of biology, discloses PDCoV recombinant RBD protein and IgA ELISA kit thereof, and the amino acid sequence of the recombinant RBD protein is shown as SEQ ID NO.1.The recombinant RBD protein is used for indirect ELISA kit, can cover early IgA response of infection, can accurately recognize PDCoV specific IgA antibody in breast milk sample, and will not cause false positive due to infection of other common pathogens in a pig herd; the indirect ELISA kit of the application is stable (the batch variation coefficient is 1.848%~6.062%, and the batch variation coefficient is 4.504%~7.790%), and the coincidence rate with an immunofluorescence experiment reaches 93.26%, the repeatability and the coincidence rate are high, the method has the advantages of simple operation, short time consumption and large detection flux, and is suitable for large-scale screening of clinical pig milk samples.

The present invention relates to homogeneous antibody-conjugates with high payload loading (high DAR) obtained by site-specific conjugation with a single antibody N-glycan. The conjugates according to the invention are homogeneous, i.e., with a DAR equal to or close to the theoretical DAR and narrow distribution, and do not require any genetic modification to the antibody. The invention also relates to a modular, non-genetic preparation method for such a conjugate, which method comprises three simple steps and can start from any antibody. These steps are (a) enzymatic remodeling of the glycan to give antibodies functionalised per antibody with two or four click probes, (b) strain-promoted cycloaddition with a multivalent bifunctional reagent comprising a cyclic alkyne and at least two click probes that are not reactive to the cyclic alkyne, and (c) strain-promoted cycloaddition with a multivalent bifunctional reagent comprising at least one cyclic alkyne and at least two click probes that are not reactive to the cyclic alkyne. And (c) subjecting the click probes to reverse electron demanding Diels-Alder cycloaddition with branched linker-drug constructs comprising a cyclic alkyne or strained olefin, linked to one or more payloads, preferably by cleavable linkers. The resulting conjugates have a DAR of 6 or higher, are rapidly generated, have high homogeneity and surprising stability. In addition, the HIC profile of the resulting ADC shows a relatively short retention time, and thus shows a very high potential in targeting tumor cells and / or treating cancer.

The application discloses an ELISA kit for detecting anti-human laminin gamma 1 IgA autoantibody and application thereof. The kit comprises an enzyme-labeled plate coated with human laminin gamma 1 recombinant protein. Preferably, the human laminin gamma 1 recombinant protein is deglycosylated human laminin gamma 1 recombinant protein. Further, the application also provides application of the kit in preparation of a reagent for diagnosing mucous membrane pemphigoid, in particular Laminin gamma 1 IgA type pemphigoid. The kit is the first kit for detecting human laminin gamma 1 IgA antibody by using the ELISA method, has the advantages of simple operation, short time consumption and low cost compared with traditional immunoblotting method, and adopts full-length deglycosylated laminin gamma 1 recombinant protein as an antigen, thereby solving the problem of incomplete antigen epitope coverage in the prior art, and early detection of diseases can be realized, early treatment is achieved, and the life quality of patients is improved.

The present invention relates to a construct, which comprises one or more domain, preferably at most one domain that binds one or more epitope of a single antigen; and a domain that binds FcαRI, in particular for use in the treatment of diseases with low disease-associated antigen (over)expression, e.g. wherein the disease is characterized by presence of diseased cells expressing per cell between 50.000-200.000 antigen moieties. The construct may bind at most one specific antigen moiety. The present disclosure also relates to a pharmaceutical composition comprising the construct.

A method of diagnosing pancreatic ductal adenocarcinoma (PDAC) is disclosed The method comprises detecting the presence of autoantibodies in a biological sample from a subject which bind to LEMD1 and MAGEB1 antigens. The method optionally also comprises detecting autoantibodies from one or more additional antigens selected from ACVR2B, GAGE1, TSGA10, PAGE1, BAGE4, AURKA, MAGEA10, PLEKHA5, PLK4 and XAGE3Av1. The autoantibodies can be detected by contacting the sample with immobilized LEMD1 and MAGEBB1, and optionally any other antigens listed above, so that any autoantibodies in the sample bind to the antigens. Detection antibodies, e.g. labeled anti-human IgG or IgA antibodies, can then be used to detect the bound autoantibodies, for example in a sandwich assay. Antigen complexes, a kit and a computer-implemented method of diagnosing PDAC are also disclosed.

The instant disclosure provides antibodies and antigen-binding fragments thereof that are specific for Campylobacter and, in certain embodiments, are capable of neutralizing a Campylobacter infection in a subject. In certain embodiments, the antibody or antigen binding fragment comprises an IgA antibody, such as, for example, a secretory IgA antibody. Also provided are pharmaceutical compositions comprising a disclosed antibody or antigen-binding fragment. Methods of using the antibodies, antigen-binding fragments, and compositions to treat or prevent a Campylobacter infection in a subject are also provided. In certain embodiments, recombinant secretory IgA antibodies of the instant disclosure are administered orally to a subject having or at risk of developing a Campylobacter infection.

Helicobacter pylori is a leading cause of gastric mucosal inflammation, peptic ulcers, and gastric adenocarcinoma. Emerging antimicrobial-resistant H. pylori has hampered the successful eradication of frequent chronic infections. Additionally, due to the absence of effective vaccines against H. pylori, a safe vaccine is highly demanded. Disclosed herein are innovative Protective Immunity Enhanced Salmonella Vaccine (PIESV) vector strains to deliver and express multiple H. pylori antigen genes. Immunization of mice with a vaccine delivering the HpaA, NapA (also termed Hp-NAP), UreA and UreB antigens, provided sterile protection against H. pylori SS1 infection in 7 out of 10 tested mice. Compared to the control groups that had received PBS or a PIESV with an empty vector, immunized mice exhibited specific and significant cellular recall responses and antigen-specific IgG2c, IgG1, total IgG and gastric IgA antibody titers. Importantly, the mice immunized with the vaccine candidate showed a significant reduction in a load of an unidentified Gram-positive rod-shaped bacteria in their stomach compared to the control groups. In conclusion, a Salmonella Typhimurium-based live vaccine delivering four antigens shows promise as a safe and effective vaccine against H. pylori infection.

The present invention aims to provide an intestinal commensal bacterium that increases IgA levels in breast milk. The agent for increasing IgA antibody levels in breast milk comprises one or more strains selected from the following: a Bacteroides strain having a 16S rRNA gene that is at least 90% identical to the nucleotide sequence represented by SEQ ID NO: 1 and increases IgA antibody levels in breast milk; and a Prevotella strain having a 16S rRNA gene that is at least 90% identical to the nucleotide sequence represented by SEQ ID NO: 2 and increases IgA antibody levels in breast milk.

The present invention discloses a kit and a detection kit for detecting herpes simplex virus in tears, the kit comprises: a housing, which comprises an internal cavity, and a sample application area and a detection window which are respectively communicated with the internal cavity; the immunochromatography test strip comprises a sample pad, a release pad and a nitrocellulose membrane which are connected in sequence, the immunochromatography test strip is arranged in the inner containing cavity, and part or all of the sample pad extends to the sample application area; the sampling assembly is in pivot connection with the shell and limits a first limit position, and when the sampling assembly is located at the first limit position, the sampling assembly is in surface contact with the sample pad; wherein herpes simplex virus type 1 G glycoprotein marked by fluorescence is embedded on the release pad; the nitrocellulose membrane is provided with a detection line and a quality control line, the detection line is coated with an anti-human IgA antibody, the quality control line is coated with a goat anti-rabbit IgG antibody, and the detection line and the quality control line are exposed to the detection window.

This invention belongs to the field of reagent detection technology and discloses a diagnostic kit for P200 type pemphigus. The kit comprises human dermal extract protein strips, LM521 / LM421 / LM411 / LM111 recombinant protein strips, a positive control, a negative control, enzyme-labeled IgG antibody, enzyme-labeled IgA antibody, reaction buffer, washing buffer, and enzyme matrix solution. This invention simplifies the complex immunoblotting technique, using human dermal extract and various LMγ1 recombinant protein mixtures as antigens, and simultaneously analyzing IgG and IgA autoantibodies. It comprehensively solves the serological diagnostic problem of P200 type pemphigus in one step.

The present disclosure provides antibodies that specifically bind to and in some cases inhibit the human glucose-dependent insulinotropic polypeptide (GIP) receptor. The antibodies find use in a variety of treatment, diagnostic, and monitoring applications, which are also described. For example, the antibodies may be used to treat a metabolic disorder, such as a disorder of glucose metabolism. In some embodiments, the antibody may have CDRs that are selected from any of the antibodies set forth in FIG. 9 or 10.

The application discloses a novel coronavirus vaccine for promoting specific IgA antibody secretion and a construction method and application thereof, belongs to the field of immunology and the field of genetic engineering, and is an immunogen developed by taking S protein as the vaccine (the same is true for other structural proteins of the novel coronavirus, such as N protein or E protein or M protein), aims to improve the mucosal IgA expression level after immunization of the vaccine, and constructs a novel coronavirus vaccine which can significantly promote human B lymphocytes to secrete specific anti-S protein IgA antibodies in the process of stimulating the immune response of the body by the S protein, and further enhance the mucosal protection and defense function, and provides a construction technology, method and application thereof. By introducing a specific protein domain, IL-5 (referred to as 'adjuvant protein'), into the S protein of the novel coronavirus, a novel coronavirus vaccine modified by the 'adjuvant protein' is formed.